Imagine your immune system as a security team trying to stop a thief. In lung cancer, the thief wears a disguise based on specific genetic changes. This review looks at how those genetic changes, like EGFR or KRAS mutations, actively shape the environment around the tumor. They can hide the thief's identity or turn off the alarm signals your immune cells use to attack.
The study found that the effectiveness of immunotherapy varies wildly depending on which genetic driver is present. These drivers regulate how the tumor presents antigens, how immune cells infiltrate the area, and how the tumor signals to the rest of the body. Because of this, a treatment that works for one person might fail for another simply because of their specific genetic profile.
This information provides a strong reason to design future clinical trials that match patients to treatments based on their genetics. However, since this is a narrative review, there are no specific trial numbers or safety data to report. The certainty of these findings is based on expert analysis rather than a single large study, so do not expect specific percentages or event rates here.